BioCryst Pharmaceuticals, Inc. (BCRX)
8.87
+0.04
(+0.45%)
USD |
NASDAQ |
May 07, 15:45
BioCryst Pharmaceuticals SG&A Expense (TTM) : 266.18M for March 31, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Anika Therapeutics, Inc. | 53.95M |
| KalVista Pharmaceuticals, Inc. | 191.34M |
| Lantheus Holdings, Inc. | 453.81M |
| Revolution Medicines, Inc. | 195.04M |
| Plus Therapeutics, Inc. | 12.13M |